- Leading Global CRO and Global Biopharmaceutical Company Extend
Relationship to Accelerate Drug Development -
WILMINGTON, Mass.--(BUSINESS WIRE)--Jul. 30, 2015--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has extended its initial three-year partnership with
AstraZeneca (NYSE: AZN) for an additional five-year period. Under the
agreement, which extends into 2020, Charles River retains its position
as AstraZeneca’s preferred strategic partner for outsourced regulated
safety assessment and development DMPK (drug metabolism and
pharmacokinetics).
James C. Foster, Chairman, President and Chief Executive Officer of
Charles River said, “We are extremely pleased that AstraZeneca has
chosen to extend its relationship with Charles River. Our combined
scientific expertise has been pivotal to enabling AstraZeneca to create
a flexible research platform to deliver innovative health solutions. We
are proud of the success of our collaboration and look forward to
providing ongoing support for AstraZeneca’s early-stage research
programs.”
Stefan Platz, Vice President, Global Safety Assessment, AstraZeneca
said, “Based on the success of our partnership with Charles River in the
first three years, we are very pleased to renew our agreement for an
additional five-year period. As we expected, partnering with Charles
River to utilize their scientific expertise enabled AstraZeneca to
increase our resource flexibility while simplifying the way we work. Our
partnership has provided substantial benefits in support of our efforts
to deliver safe and effective new treatments to patients more
efficiently, and we look forward to continuing to work productively with
Charles River for many more years.”
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words such as
“anticipate,” “believe,” “expect,” “will,” “may,” “estimate,” “plan,”
“outlook,” and “project” and other similar expressions that predict or
indicate future events or trends or that are not statements of
historical matters. Forward-looking statements include statements in
this press release regarding Charles River’s expectations with respect
to the impact of the AstraZeneca agreement on the Company.
Forward-looking statements are based on Charles River’s current
expectations and beliefs, and involve a number of risks and
uncertainties that are difficult to predict and that could cause actual
results to differ materially from those stated or implied by the
forward-looking statements. A further description of these risks,
uncertainties, and other matters can be found in the Risk Factors
detailed in Charles River's Annual Report on Form 10-K as filed on
February 17, 2015, as well as other filings we make with the Securities
and Exchange Commission. Because forward-looking statements involve
risks and uncertainties, actual results and events may differ materially
from results and events currently expected by Charles River, and Charles
River assumes no obligation and expressly disclaims any duty to update
information contained in this news release except as required by law.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of cardiovascular,
metabolic, respiratory, inflammation, autoimmune, oncology, infection
and neuroscience diseases. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
For more information please visit: www.astrazeneca.com.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150730005360/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
Investors:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media:
Amy
Cianciaruso, 781-222-6168
Executive Director, Public Relations
amy.cianciaruso@crl.com
